Construction and application of a heterogeneous quality control library for the Xpert MTB/RIF assay in tuberculosis diagnosis

被引:0
作者
Guan, Zehao [1 ]
Han, Xuefei [1 ]
Huang, Weigang [1 ]
Wang, Xueliang [1 ]
Wang, Hualiang [1 ,2 ]
Fan, Yun [1 ]
机构
[1] Shanghai Ctr Clin Lab, R&D Lab Qual Control Mat, Shanghai, Peoples R China
[2] Shanghai Acad Expt Med, Shanghai, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2023年 / 13卷
关键词
Mycobacterium tuberculosis; Xpert MTB; RIF assay; quality control material; proficiency testing; heterogeneous host; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; RPOB MUTATIONS; RIFAMPIN;
D O I
10.3389/fcimb.2023.1128337
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Proficiency testing based on quality control materials is an important component of the quality assurance system for detection methods. However, in the detection of infectious diseases, it is a challenge to use quality control materials derived from clinical samples or pathogens owing to their infectious nature. The Xpert MTB/RIF assay, endorsed by the World Health Organization, is one of the most widely implemented assays in the detection of Mycobacterium tuberculosis along with rifampicin resistance and its heterogeneity. Clinical isolates are typically used as quality controls for this assay, leading to concerns about biosafety, constrained target sequence polymorphisms, and time-consuming preparation. In this study, a heterogeneous quality control library for the Xpert MTB/RIF assay was constructed based on DNA synthesis and site-directed mutation, which provides sufficient rifampicin resistance polymorphisms, enabling monitoring all five probes of Xpert MTB/RIF and its combinations. Escherichia coli and Bacillus subtilis were used as heterogeneous hosts rather than the pathogen itself to eliminate biosafety risks; thus, preparation does not require a biosafety level III laboratory and the production time is reduced from a few months to a few days. The panel was stable for more than 15 months stored at 4 degrees C and could be distributed at room temperature. All 11 laboratories in Shanghai participating in a pilot survey identified the specimens with corresponding probe patterns, and discordant results highlighted inappropriate operations in the process. Collectively, we show, for the first time, that this library, based on heterogeneous hosts, is an appropriate alternative for M. tuberculosis detection.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Performance of Xpert MTB/RIF Assay in Diagnosis of Pleural Tuberculosis by Use of Pleural Fluid Samples
    Rufai, Syed Beenish
    Singh, Amit
    Kumar, Parveen
    Singh, Jitendra
    Singh, Sarman
    JOURNAL OF CLINICAL MICROBIOLOGY, 2015, 53 (11) : 3636 - 3638
  • [22] Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - Report from a developing country
    Iram, Shagufta
    Zeenat, Asyia
    Hussain, Shahida
    Yusuf, Noshin Wasim
    Aslam, Maleeha
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2015, 31 (01) : 105 - 110
  • [23] Evaluation of Xpert MTB/RIF Ultra Assay for Diagnosis of Childhood Tuberculosis: a Multicenter Accuracy Study
    Sun, Lin
    Zhu, Yu
    Fang, Min
    Shi, Yan
    Peng, Xiaoshan
    Liao, Qiong
    Wang, Xingyun
    Quan, Shuting
    Wang, Yacui
    Duan, Li
    Shi, Xiaomei
    Zhao, Zhipeng
    Chen, Lanqin
    Xu, Yongsheng
    Zhang, Tongqiang
    Cui, Xiaojian
    Wan, Chaomin
    Shen, Adong
    JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (09)
  • [24] Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis
    Denkinger, Claudia M.
    Schumacher, Samuel G.
    Boehme, Catharina C.
    Dendukuri, Nandini
    Pai, Madhukar
    Steingart, Karen R.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44 (02) : 435 - 446
  • [25] Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
    Steingart, Karen R.
    Schiller, Ian
    Horne, David J.
    Pai, Madhukar
    Boehme, Catharina C.
    Dendukuri, Nandini
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (01):
  • [26] Efficacy of the Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis
    Tabriz, Nurlan S.
    Skak, Kuliya
    Kassayeva, Lazzat T.
    Omarkulov, Bauyrzhan K.
    Grigolashvili, Marina A.
    MICROBIAL DRUG RESISTANCE, 2020, 26 (08) : 997 - 1004
  • [27] Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting
    Theron, Grant
    Peter, Jonny
    van Zyl-Smit, Richard
    Mishra, Hridesh
    Streicher, Elizabeth
    Murray, Samuel
    Dawson, Rodney
    Whitelaw, Andrew
    Hoelscher, Michael
    Sharma, Surendra
    Pai, Madhukar
    Warren, Robin
    Dheda, Keertan
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (01) : 132 - 140
  • [28] Application of CBNAAT (Xpert MTB/RIF assay) in new smear negative pulmonary tuberculosis patients
    Chopra, Vishal
    Virk, Baljeet Singh
    Chopra, Siddharth
    Bansal, Monika
    Chungath, Jain
    MONALDI ARCHIVES FOR CHEST DISEASE, 2020, 90 (01) : 105 - 109
  • [29] Comparison of xpert MTB/RIF assay, line probe assay, and culture in diagnosis of pulmonary tuberculosis on bronchoscopic specimen
    Kanade, Swapna
    Mohammed, Zakiuddin
    Kulkarni, Anisha
    Nataraj, Gita
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2023, 12 (02) : 151 - 156
  • [30] Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children
    Kay, Alexander W.
    Fernandez, Lucia Gonzalez
    Takwoingi, Yemisi
    Eisenhut, Michael
    Detjen, Anne K.
    Steingart, Karen R.
    Mandalakas, Anna M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (08):